Aelis Farma
- Address
- 1 Rue Lafaurie De Monbadon
Sponsor Overview
Specializations
Cannabinoid Receptor Modulation
The sponsor focuses on innovative approaches to cannabinoid receptor signaling, specifically targeting the CB1 receptor pathway. Research efforts concentrate on developing selective modulators that can influence endocannabinoid system activity without producing the typical effects associated with cannabinoid compounds. This work represents a novel strategy in cannabinoid pharmacology, aiming to harness therapeutic benefits while minimizing unwanted receptor activation.
- Selective CB1 receptor modulation
- Endocannabinoid system targeting
- Cannabinoid signaling pathways
The therapeutic development emphasizes precision targeting of cannabinoid receptor subtypes to achieve specific pharmacological outcomes in conditions where the endocannabinoid system plays a significant role.
Substance Use Disorders
A primary area of investigation involves addressing cannabis use disorder and related substance dependence conditions. The research explores novel pharmacological interventions for individuals experiencing problematic patterns of substance consumption. This work targets the neurobiological mechanisms underlying addiction pathology and compulsive drug-seeking behavior, with particular emphasis on cannabis-related disorders.
- Cannabis use disorder treatment
- Addiction neurobiology
- Substance dependence interventions
The therapeutic approach seeks to address the complex interplay between reward circuitry, behavioral reinforcement, and neurochemical adaptation that characterizes substance use disorders.
Neuropsychiatric Disorders
Research activities extend to various neuropsychiatric conditions where cannabinoid system modulation may offer therapeutic benefit. The sponsor investigates applications in cognitive dysfunction, behavioral disorders, and conditions involving dysregulated neural signaling pathways. This encompasses disorders where the endocannabinoid system contributes to symptom manifestation or disease progression.
- Cognitive impairment treatment
- Behavioral disorder management
- Neural pathway modulation
The investigation focuses on conditions where cannabinoid receptor dysfunction or altered endocannabinoid tone may represent viable therapeutic targets for symptom control and functional improvement.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Efficacy and Safety of AEF0217 in Treating Behavioral and Cognitive Impairments in Adults and Adolescents with Down Syndrome: A Phase 2B Randomized Controlled Trial |  France Italy Spain | Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 1 is not being studied by other sponsors.
This sponsor has worked with 10 sites across their trial portfolio.
Therapeutic Focus
- 1.Congenital, Hereditary, and Neonatal Diseases and Abnormalities1 trial165 other sponsors
Partnered Research Centres
10 centres- Address
- Via Conte Ruggero 73, 94018 Troina
- Address
- Via Altura 3, 40139 Bologna
- Address
- 165 Chemin Du Grand Revoyet, 69310 Pierre Benite
- Address
- 1 Rue Jean Burguet, 33000 Bordeaux
- Address
- 80 Avenue Augustin Fliche, 34295 Montpellier
- Address
- Largo Francesco Vito 1, 00168 Rome
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Aelis Farma.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.